Home » Stocks » Frequency Therapeutics

Frequency Therapeutics, Inc. (FREQ)

Stock Price: $22.95 USD 0.00 (0.00%)
Updated Jul 9, 2020 8:08 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 711.75M
Revenue (ttm) 36.21M
Net Income (ttm) n/a
Shares Out 31.01M
EPS (ttm) -10.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $22.95
Previous Close $22.95
Change ($) 0.00
Change (%) 0.00%
Day's Open 22.45
Day's Range 21.70 - 23.08
Day's Volume 977
52-Week Range 11.17 - 28.78

More Stats

Market Cap 711.75M
Enterprise Value 506.28M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 31.01M
Float 23.30M
EPS (basic) n/a
EPS (diluted) -10.29
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.78M
Short Ratio 11.67
Short % of Float 9.94%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19.66
PB Ratio 4.14
Revenue 36.21M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 205.48M
Net Cash / Share 6.63
Gross Margin 35.75%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -9.65%
ROE -17.38%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$29.50*
(28.54% upside)
Low
27.0
Current: 22.95
High
32.0
Target: 29.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue28.95--
Gross Profit28.95--
Operating Income-20.68-18.94-16.31
Net Income-18.75-19.17-20.24
Shares Outstanding8.651.530.70
Earnings Per Share-2.29-12.53-28.79
Operating Cash Flow34.22-17.02-14.61
Capital Expenditures-1.06-0.44-1.86
Free Cash Flow33.15-17.46-16.48
Cash & Equivalents21742.1917.94
Net Cash / Debt21742.1917.94
Assets22344.5519.79
Liabilities55.864.122.74
Book Value167-52.06-29.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Frequency Therapeutics, Inc.
Country United States
Employees 43
CEO David L. Lucchino

Stock Information

Ticker Symbol FREQ
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FREQ

Description

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.